In the BioHarmony Drug Report Database
Dihydroergotamine
D.h.e, Migranal (dihydroergotamine) is a small molecule pharmaceutical. Dihydroergotamine was first approved as D.h.e on 1982-01-01. It is used to treat cluster headache, migraine disorders, orthostatic hypotension, postpartum hemorrhage, and xerostomia in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 6.
Trade Name
|
D.h.e., Migranal |
|---|---|
Common Name
|
dihydroergotamine |
ChEMBL ID
|
CHEMBL1732 |
Indication
|
cluster headache, migraine disorders, orthostatic hypotension, postpartum hemorrhage, xerostomia |
Drug Class
|
Ergot alkaloid derivatives |
Image (chem structure or protein)